Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Laboratorio Farmaceutico Erfo S.p.A.: Strengths and Weaknesses

Weaknesses: Laboratorio Farmaceutico Erfo S.p.A.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Consensus

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

-

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1.11Cr - - - - -
1,03700Cr
A
62TCr
BBB
45TCr
AA
-
33TCr
AA
29TCr
AAA
26TCr
A
22TCr
A
20TCr
A
16TCr
AA
Average 35.57TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ERFO Stock
  4. Ratings Laboratorio Farmaceutico Erfo S.p.A.